•  
  •  
  •  
  •  

2026-07-25 04:14:14

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • TANFAC Industries Reports Q1 FY27 Net Profit of ₹16.85 Crore; Operational Revenue Up 6.3% YoY to ₹187.18 Crore
  • New India Assurance Reports Q1 FY27 Net Loss of ₹243.94 Crore; Gross Written Premium Rises 2.9% YoY to ₹13,835 Crore
  • NTPC Consolidated Q1 FY27 Net Profit Rises 12.9% YoY to ₹6,896 Crore; Operational Revenue Up 7.8% at ₹50,741 Crore
  • Neogen Chemicals Reports Q1 FY27 Net Profit Surge of 66.8% YoY to ₹17.11 Crore; Operational Revenue Up 34% at ₹250.29 Crore
  • Arihant Capital Markets Reports Q1 FY27 Net Profit of ₹21.49 Crore, Up 69.2% YoY; Operational Revenue Jumps 53.5%

Keywords Selected:  PreApprovalInspection

Stock Report

  • Glenmark Pharmaceuticals Ltd update on USFDA PAI at Chhatrapati Sambhajinagar Facility
  • Closure of USFDA inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Lupin gets one observation from USFDA for Somerset, New Jersey manufacturing facility
  • Lupin gets 4 observations from USFDA from PAI at Pune Biotech facility
  • USFDA conducts product specific pre-approval inspection at Lupin Ltd's Aurangabad facility
  • Granules India Ltd receives 1 observation from USFDA for Chantilly facility
  • Gland Pharma Ltd receives EIR from US FDA for JNPC Facility, Visakhapatnam
  • Piramal Pharma Limited's Ahmedabad facility successfully completes USFDA Pre-Approval Inspection
  • Torrent Pharmaceuticals Ltd gets Form 483 with 5 observations for Indrad facility
  • Piramal Pharma Ltd gets Form 483 with 2 observations from USFDA for Lexington, USA facility
  • Torrent Pharmaceuticals Ltd gets Form 483 from USFDA after Pre-Approval Inspection for Bileshwarpura facility
  • Bajaj Healthcare Ltd receives EIR from USFDA for API manufacturing facility in Savli
  • Aurobindo Pharma Ltd's Unit 7 completes USFDA PAI successfully
  • US FDA Inspection at Pashmylaram Facility, Hyderabad of Gland Pharma Ltd
  • Zydus Lifesciences Ltd gets 3 observations from USFDA for Pharmex, Ahmedabad facility
  • Bliss GVS Pharma Ltd gets 3 minor observations from USFDA for Palghar unit
  • USFDA Pre-Approval Inspection of Oral Oncology Manufacturing facility, Gujarat
  • Granules India Ltd gets 3 observations from USFDA for Gagillapur facility
  • Alembic Pharmaceuticals gets 5 observations from USFDA for Solid Oral Formulation Facility (F-4) at Jarod
  • Bajaj Healthcare Ltd announces successful completion of USFDA pre approval inspection at API facility
  • Syngene International Ltd update on USFDA Inspection of Biologics facility
  • Laurus Labs Ltd gets one observation from USFDA for Pre-Approval Inspection
  • Cipla Ltd receives EIR for Indore plant
  • US FDA inspection at Alkem's manufacturing facility located at St. Louis, USA

Latest Post

  • TANFAC Industries Reports Q1 FY27 Net Profit of ₹16.85 Crore; Operational Revenue Up 6.3% YoY to ₹187.18 Crore
  • New India Assurance Reports Q1 FY27 Net Loss of ₹243.94 Crore; Gross Written Premium Rises 2.9% YoY to ₹13,835 Crore
  • NTPC Consolidated Q1 FY27 Net Profit Rises 12.9% YoY to ₹6,896 Crore; Operational Revenue Up 7.8% at ₹50,741 Crore
  • Neogen Chemicals Reports Q1 FY27 Net Profit Surge of 66.8% YoY to ₹17.11 Crore; Operational Revenue Up 34% at ₹250.29 Crore
  • Arihant Capital Markets Reports Q1 FY27 Net Profit of ₹21.49 Crore, Up 69.2% YoY; Operational Revenue Jumps 53.5%


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025